|
[1]
|
Weidinger, S., Beck, L.A., Bieber, T., Kabashima, K. and Irvine, A.D. (2018) Atopic Dermatitis. Nature Reviews Disease Primers, 4, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Frazier, W. and Bhardwaj, N. (2020) Atopic Dermatitis: Diagnosis and Treatment. American Family Physician, 101, 590-598.
|
|
[3]
|
齐雨婷, 靳清清, 陈果, 等. 抗IL-13抗体治疗中重度特应性皮炎疗效与安全性的荟萃分析[J]. 中国免疫学杂志. 2022, 38(6): 738-744.
|
|
[4]
|
Sroka-Tomaszewska, J. and Trzeciak, M. (2021) Molecular Mechanisms of Atopic Dermatitis Pathogen-esis. International Journal of Molecular Sciences, 22, Article 4130. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Tominaga, M. and Takamori, K. (2022) Peripheral Itch Sensitization in Atopic Dermatitis. Allergology International, 71, 265-277. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Silverberg, J.I., Garg, N.K., Paller, A.S., Fishbein, A.B. and Zee, P.C. (2015) Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Popula-tion-Based Study. The Journal of Investigative Dermatology, 135, 56-66. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Sacotte, R. and Silverberg, J.I. (2018) Epidemiology of Adult Atopic Dermatitis. Clinics in Dermatology, 36, 595-605. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Barbarot, S., Silverberg, J.I., Gadkari, A., et al. (2022) The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-Sectional Study. The Journal of Pediatrics, 246, 220-226. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Ali, F., Vyas, J. and Finlay, A.Y. (2020) Counting the Burden: Atopic Dermatitis and Health-Related Quality of Life. Acta Dermato-Venereologica, 100, 330-340. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Salvati, L., Cosmi, L. and Annunziato, F. (2021) From Emollients to Biologicals: Targeting Atopic Dermatitis. International Journal of Molecular Sciences, 22, Article 10381. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lin, T.K., Zhong, L. and Santiago, J.L. (2017) Association between Stress and the HPA Axis in the Atopic Dermatitis. International Journal of Molecular Sciences, 18, Article 2131. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Paller, A., Kabashima, K., Bieber, T., et al. (2017) Therapeutic Pipeline for Atopic Dermatitis: End of the Drought? 140, 633-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Singh, I., Chat, V.S., Uy, A., et al. (2022) Who Sees You Matters: A Population Study Examining Topical Corticosteroid Pre-scribing Patterns between Primary Care Providers and Dermatologists for Atopic Dermatitis. The Journal of Dermato-logical Treatment, 33, 1507-1510. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Eichenfield, L., Tom, W., Berger, T., et al. (2014) Guidelines of Care for the Management of Atopic Dermatitis: Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. Journal of the American Academy of Dermatology, 71, 116-132.
|
|
[15]
|
Ramachandran, V., Cline, A., Feldman, S. and Strowd, L.C. (2019) Evaluating Crisaborole as a Treatment Option for Atopic Dermatitis. Expert Opinion on Pharmacotherapy, 20, 1057-1063. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
梁龙铭. 磷酸二酯酶4抑制剂ZL-n-91对三阴性乳腺癌的治疗作用及机制研究[D]: [硕士学位论文]. 广州: 广东工业大学, 2022.
|
|
[17]
|
王惠芳, 王有志, 支运宝, 等. 磷酸二酯酶4抑制剂临床及安全性研究进展[J]. 药学学报, 1-13.
|
|
[18]
|
Lugnier, C. (2022) The Complexity and Multi-plicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches. Interna-tional Journal of Molecular Sciences, 23, Article 10616. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Jarnagin, K., Chanda, S., Coronado, D., et al. (2016) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Develop-ment for the Treatment of Atopic Dermatitis. Journal of Drugs in Dermatology: JDD, 15, 390-396.
|
|
[20]
|
王洁, 金珊, 朱莲花, 等. 外用磷酸二酯酶4抑制剂在特应性皮炎中的研究进展[J]. 中国皮肤性病学杂志[J]. 2022, 36(10): 1216-1220.
|
|
[21]
|
Zane, L., Kircik, L., Call, R., et al. (2016) Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatric Dermatology, 33, 380-387. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Tom, W., Van Syoc, M., Chanda, S., et al. (2016) Pharmaco-kinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Pediatric Dermatology, 33, 150-159. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Paller, A., Tom, W., Lebwohl, M., et al. (2016) Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phos-phodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults. Journal of the American Academy of Dermatology, 75, 494-503. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Bissonnette, R., Pavel, A., Diaz, A., et al. (2019) Crisaborole and Atopic Dermatitis Skin Biomarkers: An Intrapatient Randomized Trial. Journal of Allergy and Clinical Immunology, 144, 1274-1289. [Google Scholar] [CrossRef] [PubMed]
|